- Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
- Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
- Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
- Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
- Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
- Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
- Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023
- Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
More ▼
Key statistics
On Tuesday, Vir Biotechnology Inc (VIR:NSQ) closed at 8.46, 11.17% above the 52 week low of 7.61 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.36 |
---|---|
High | 8.49 |
Low | 8.20 |
Bid | 7.68 |
Offer | 8.44 |
Previous close | 8.37 |
Average volume | 925.33k |
---|---|
Shares outstanding | 135.84m |
Free float | 116.63m |
P/E (TTM) | -- |
Market cap | 1.14bn USD |
EPS (TTM) | -4.59 USD |
Data delayed at least 15 minutes, as of Apr 30 2024 21:00 BST.
More ▼